VICTORIA, BC, Sept. 10, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES
LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF) (
FSE:TQB2), a provider of best-in-class therapeutic antibody
discovery capabilities for the global pharmaceutical and biotech
industries, is pleased to announce that it has commenced the
application process to dual list its stock on the NASDAQ Capital
Market ("NASDAQ").
By listing on NASDAQ, the Company believes that it will gain
greater exposure and access to a larger base of retail and
institutional investors in the United
States and internationally. NASDAQ is the world's
pre-eminent exchange for biotech and pharma companies.
The listing of the Company's common shares on NASDAQ remains
subject to the approval of the exchange and satisfaction of all
applicable listing requirements. The Company plans to provide
updates on its progress as it advances toward this goal.
Dr. Jennifer Bath, CEO of
ImmunoPrecise, comments, "We have worked very hard to meet the
requirements for Nasdaq and believe that we meet substantially all
the requirements. Our plan to move to a senior U.S. exchange
reflects our success and momentum in growing our CRO business, as
well as advancement of our robust therapeutic pipeline. Moreover,
we believe that listing on Nasdaq will provide a broader platform
as we execute on upcoming catalysts, including near-term milestones
related to our COVID-19 therapeutic and diagnostic programs.
We believe that listing on Nasdaq will also help broaden our
shareholder base, increase appeal to institutional investors, allow
for inclusion in key indexes and ETFs, as well as provide
shareholders with enhanced liquidity."
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a global technology platform company with
end-to-end solutions empowering companies to discover and develop
therapies against any disease. The Company's experience and
cutting-edge technologies enable unparalleled support of its
partners in their quest to bring innovative treatments to the
clinic. ImmunoPrecise's full-service capabilities dramatically
reduce the time required for, and the inherent risk associated
with, conventional multi-vendor product development. For further
information, visit www.immunoprecise.com or contact
solutions@immunoprecise.com.
Forward Looking Information
This news release contains statements that, to the extent
they are not recitations of historical fact, may constitute
"forward-looking statements" within the meaning of applicable
Canadian securities laws. The Company uses words such as "may",
"would", "could", "will", "likely", "expect", "believe", "intend"
and similar expressions to identify forward-looking statements.
These statements include, but are not limited to, statements
regarding the Company's plan and ability to list on NASDAQ.
Any such forward-looking statements are based on assumptions and
analyses made by ImmunoPrecise in light of its experience and its
perception of historical trends, current conditions and expected
future developments. However, whether actual results and
developments will conform to ImmunoPrecise's expectations and
predictions is subject to any number of risks, assumptions and
uncertainties. Many factors could cause ImmunoPrecise's actual
results to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such
factors include, among other things, the Company's ability to
complete the NASDAQ listing process in a timely manner or at all,
actual revenues and earnings for IPA being lower than anticipated,
and those risks and uncertainties described in ImmunoPrecise's
annual management discussion and analysis for the previous quarter
ended January 31, 2020 which can be
accessed at www.sedar.com. The "forward-looking
statements" contained herein speak only as of the date of this
press release and, unless required by applicable law, ImmunoPrecise
undertakes no obligation to publicly update or revise such
information, whether as a result of new information, future events
or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/immunoprecise-commences-application-process-to-dual-list-on-nasdaq-301127342.html
SOURCE ImmunoPrecise Antibodies Ltd.